Global Immunostimulants Market is anticipated to increase from 2022 to 2032, expanding at a 6.2% CAGR and reaching roughly US$108.2 billion in 2022. According to a recent analysis by Future Market Insights, vaccines will represent more than 62% of the global market for immunostimulants in 2021. (FMI).
Immunostimulants are being developed as autoimmune illnesses are becoming more common. Multiple sclerosis and rheumatoid arthritis are among the autoimmune illnesses that affect roughly 4% of the world’s population. Autoimmune disorders rank third among chronic illnesses in the United States.
Further, demand for immunostimulants in countries such as India and China is expected to increase at a considerable pace. Developing economies are refining their healthcare framework, owing to increasing accessibility to resources, and increasing efforts by manufacturers to gain drug approvals for international retail.
Get a Full PDF Sample Copy of the Latest Reports @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15145
For instance, in November 2021, PharmaEssentia Corporation, a company based in Taiwan, announced that the U.S. Food and Drug Administration (FDA) has approved BESREMi, long-acting interferon for the treatment of adults with polycythemia vera.
“Rising awareness regarding immunostimulants therapy for chronic diseases across emerging economies, along with increasing investments in the pharmaceutical and healthcare sectors will fuel the growth in the market over the forecast period,” says an FMI analyst.
Key Takeaways:
- Based on product type, demand for vaccines is expected to increase at a 6.4% CAGR over the forecast period.
- In terms of application, the oncology segment will account for 34.7% of the total market share by 2032.
- By end user, hospital pharmacies held 34.3% of the total market share in 2021 and the trend is expected to continue over the forecast period.
- The U.S. accounted for 92.85 of the North America immunostimulants market in 2021.
- Sales in the Germany immunostimulants market are forecast to increase at a 6.4% CAGR over the assessment period.
- Demand for immunostimulants in Japan will grow at a 6% CAGR over the forecast period.
Are you looking for customized information related to the latest trends, drivers, and challenges? Speak to Our Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-15145
Competition Landscape
Leading players operating in the global immunostimulants market are investing in acquisitions and collaborations to expand their global presence. They are also investing in research and development to improve their product portfolios.
Key Players
F. Hoffmann-La Roche Ltd, Merck KGaA, Bayer AG, Biogen Idec, GenSci, Sinovac, BioLegend, Invitrogen, OriGene, Biorbyt, Qilu Pharmaceutical, Shijiazhuang Pharmaceutical, Amgen Inc, Johnson & Johnson, Kyowa Hakko Kirin, Bristol-Myers Squibb, Zydus Cadila, Novartis AG, Pfizer Inc, Amega Biotech, 3Sbio, Biosidus, Nanogen
For instance:
- In August 2021, Bayer AG acquired Vividion Therapeutics to strengthen its drug discovery platform to meet the high unmet medical needs for immune-related diseases and for oncology.
- In August 2020, Bristol Myers Squibb collaborated with Dragonfly Therapeutics and announced an exclusive global license for Dragonfly’s IL-12 investigational immunotherapy program.
To Buy this Report Visit @ https://www.futuremarketinsights.com/checkout/15145
Key Market Segments Covered in Immunostimulants Industry Research
By Product:
- Colony Stimulating Factors
- Interferons
- Interleukins
- Vaccines
By Application:
- Oncology
- Respiratory
- Chronic & Autoimmune Disorders
- Others
By End-User:
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Clinics
- Online Pharmacies
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
